ADVERTISEMENT

Adam Asch

Magrolimab in Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes: 5F9005 Phase 1b Study Results

Introduction:

Deepa Jeyakumar ;

Eunice S. Wang ;

Joshua F. Zeidner ;

David A. Sallman ;

Daniel A. Pollyea , MD, MS;

Guillermo Garcia-Manero , MD;

Naval G. Daver ;

Joseph G. Jurcic ;

Suman N. Kambhampati ;

Monzr M. Al Malki ;

Tiffany N. Tanaka ;

Terrence J. Bradley ;

11/04/2022

Tolerability and Efficacy of the First-in-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia: Phase 1b Results

Introduction:

Joshua F. Zeidner ;

Suman N. Kambhampati ;

David A. Sallman ;

Monzr M. Al Malki ;

Richard Larson ;

Gabriel Mannis ;

Wanxing Chai-Ho ;

Tiffany N. Tanaka ;

Terrence J. Bradley ;

Deepa Jeyakumar ;

Eunice S. Wang ;

Giri Ramsingh ;

Camille Renard ;

Naval G. Daver ;

11/04/2022

The PI3K Inhibitor ME-401 ± Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Purpose of the Study: ME-401, a potent and selective oral PI3k inhibitor, is being evaluated in a Phase 1b study in patients (pts) with R/R B-cell malignancies (NCT02914938). 101 pts were...

Igor Gorbatchevsky ;

Andrew Zelenetz ;

Nishitha Reddy ;

Deepa Jagadeesh ;

Anastasios Stathis ;

Jacob Soumerai ;

Vaishalee Kenkre ;

Haresh Jhangiani ;

Judith Llorin-Sangalang ;

10/22/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Advertisement

Advertisement

Advertisement

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

See Full Calendar

Advertisement

Advertisement